Edwards Lifesciences stock underperformed its peers on Friday, sliding on light sales of its transcatheter aortic heart-valve replacements.
Q1 2024 Edwards Lifesciences Corp Earnings Call
Edwards Lifesciences reports a strong start to 2024 with significant sales increases and raised financial forecasts.